Rasagiline (Azilect AGN 1135) is an irreversible inhibitor of monoamine oxidase used as a monotherapy in early Parkinson’s disease or as an adjunct therapy in more advanced cases. It is selective for MAO type B over type A by a factor of fourteen.It was developed by Teva Neuroscience initially investigated by Prof. Moussa B.H. Youdim and Prof. John Finberg of the Faculty of Medicine Technion – Israel Institute of Technology.
This page contains content from the copyrighted Wikipedia article "Rasagiline"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
